Twelve companies in the Class of 2003 now have later-stage compounds, albeit not always the one that was the lead compound in the 2003 European Iceberg survey. These companies have raised at least $1.7 billion. $M; Source: BCIQ: BioCentury Online Intelligence       

Company

Raised

2003 status

2010 lead

2010 status [indication]

Focus

Antisense Pharma GmbH

$104.9

Ph II

Trabedersen (AP 12009)

Ph III [glioma]

Platform: antisense technology